SCHEMBL26027248

SCHEMBL26027248

CC(C)(C)c1nnc(CS(C)(=O)=O)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA4 P22748 1/20 0.43
▸ CA5A P35218 1/20 0.43
▸ CA5B Q9Y2D0 1/20 0.43
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ ALDH1A1 P00352 9/20 0.36
▸ MAPT P10636 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ PAX8 Q06710 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ AKT1 P31749 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1272580 0.83 CA1 (0.42) CA1CA2CA4CA5ACA5B
SCHEMBL25364962 0.74 CA1 (0.35) CA1CA2CA4CA5ACA5B
SCHEMBL17240202 0.74 POLB (0.50) CA1CA2CA4CA5ACA5B
SCHEMBL10285896 0.73 SMN1; SMN2 (0.43) CA1CA2CA4CA5ACA5B
SCHEMBL10402147 0.72 ALDH1A1 (0.33) CA1CA2CA4CA5ACA5B
SCHEMBL9686627 0.72 ALDH1A1 (0.33) CA1CA2CA4CA5ACA5B
SCHEMBL744617 0.71 SMN1; SMN2 (0.42) CA1CA2CA4CA5ACA5B
SCHEMBL2540881 0.71 MEN1 (0.38) CA1CA2CA4CA5ACA5B
SCHEMBL19370115 0.71 CA1 (0.40) CA1CA2CA4CA5ACA5B
SCHEMBL10981320 0.71 MEN1 (0.39) CA1CA2CA4CA5ACA5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265057-A1 INHIBITORS OF PARG ARASE THERAPEUTICS INC. 2023-08-24 — — US disclosed
US-20230265057-A1 INHIBITORS OF PARG ARASE THERAPEUTICS INC. 2023-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265057-A1 INHIBITORS OF PARG PARG, PARN, PLG CA1 2609/4885CA2 836/4885CA4 1583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback